For several years the vaccine producer Berna Biotech a Swiss affiliate of Crucell N.V. has been working rigorously on the 3R program, which has a goal to Reduce, Refine and Replace all animal testing. The development of in-vitro alternatives as well as the strategic imperative of Berna Biotech to eliminate animal testing has resulted in the company announcing, that it will cease all animal testing and therefore close the animal house in Bern in 2008. Crucell's Swiss affiliate Berna Biotech whose goal is to fight infectious diseases and save lives by bringing innovation to global health has reached another important milestone in the production of modern vaccines.
Crucell N.V. (Euronext, NASDAQ: CRXL; Swiss Exchange: CRX) is a global
biopharma company focused on research, development, production and marketing of vaccines, proteins and antibodies that prevent and treat primarily infectious diseases. Its vaccines are sold in public and private markets worldwide.
Crucell's core portfolio includes a vaccine against hepatitis B, a fully-liquid vaccine against five important childhood diseases and a virosome-adjuvanted vaccine
against influenza. Crucell also markets travel vaccines, such as the only oral anti-typhoid vaccine, an oral cholera vaccine and the only aluminum-free hepatitis A vaccine on the market. The Company has a broad development pipeline, with several product candidates based on its unique PER.C6® production technology. The Company licenses its PER.C6® technology and other technologies to the biopharmaceutical industry. Important partners and licensees include DSM Biologics, sanofi-aventis, Novartis, Wyeth and Merck & Co. Crucell is headquartered in Leiden, the Netherlands, with subsidiaries in Switzerland, Spain, Italy, Sweden, Korea and the US. The Company employs over a 1000 people. For more information, please visit www.crucell.com.
This press release contains forward-looking statements that involve inherent risks and uncertainties. We have identified certain important factors that may cause actual results to differ materially from those contained in such forward-looking statements. For information relating to these factors please refer to our Form 20-F, as filed with the U.S. Securities and Exchange Commission on May 7, 2008, and the section entitled "Risk Factors". The Company prepares its financial statements under International Financial Reporting Standards IFRS.
For further information please contact: Crucell N.V. Oya Yavuz Director Corporate Communications Investor Relations
Copyright Copyright Hugin AS 2008. All rights reserved.
SOURCE: Crucell N.V.
Copyright 2008 Market
Wire, All rights reserved.